N/A
N=51
Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey
Hematologic Neoplasms
Bottom Line
View on ClinicalTrials.gov: NCT05061095 ↗Enrolled (actual)
51
Serious AEs
—
Results posted
Dec 2024
Primary outcome: Primary: Content Validity of Best-Worst Scaling (BWS) Survey — 10; 0 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Assessment Surveys (Other); Qualitative Interviews (Other)
- Age
- Adult, Older Adult · 60+ yrs
- Sex
- All
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Primary completion
- Sep 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Content Validity of Best-Worst Scaling (BWS) Survey |
10; 0 | — |
| SECONDARY Acceptability of Best-Worst Scaling (BWS) Survey to Patients |
13 | — |
| SECONDARY Preliminary Efficiency of Best-Worst Scaling (BWS) Survey |
9 | — |
| SECONDARY Completion Rate Over Time |
51; 27; 26; 19; 16 | — |
Summary
This study will evaluate the validity of using a survey to quantify patient preferences at the point-of-care and the potential effectiveness of the survey to improve goal-concordant care. The primary hypothesis is that by identifying the strength of patient preferences for outcomes with this survey clinicians will be able to improve goal-concordant care by aligning clinical recommendations with patients' preferences. This study will have 50 patients with newly diagnosed hematologic malignancy complete the survey throughout their disease course (up to 2 years) and conduct qualitative interviews with a subset (n = 20) of participants. The information obtained from these participants will be used to refine the survey. Interviews with oncologists and palliative care specialists (up to 10) will inform implementation.
Eligibility Criteria
Inclusion Criteria
- Confirmed new diagnosis of one of the following hematologic malignancies: aggressive lymphoma, multiple myeloma, CLL, CML, AML, ALL, MDS EB1 or EB2
- Age≥60
- Ability to read, understand, and communicate fluently in English
- Ability to understand and comply with study procedures
- Willingness and ability to provide written informed consent
Exclusion Criteria
- Dementia, altered mental status, or psychiatric condition that would prohibit the understanding or rendering of informed consent or participation in the discrete choice experiment.
- Significant medical conditions, as assessed by the investigators, that would substantially increase the burden on the patient to complete study assessments (such as multiorgan failure, respiratory failure, or other critical illness).
Data sourced from ClinicalTrials.gov (NCT05061095). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.